Longeveron (NASDAQ:LGVN) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Longeveron (NASDAQ:LGVN) from a hold rating to a sell rating in a report released on Saturday.

Other equities analysts have also issued research reports about the stock. Maxim Group lowered shares of Longeveron from a “buy” rating to a “hold” rating in a report on Monday, May 11th. HC Wainwright dropped their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Finally, Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.50.

Longeveron Price Performance

LGVN stock opened at $0.60 on Friday. The stock has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $0.75. The firm has a market cap of $18.76 million, a P/E ratio of -0.53 and a beta of -0.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88. Longeveron has a 1 year low of $0.47 and a 1 year high of $1.80.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.33 million. Longeveron had a negative return on equity of 202.41% and a negative net margin of 1,844.49%. On average, equities analysts predict that Longeveron will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Longeveron

An institutional investor recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent SEC filing. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.